Novartis AG
NVS Real Time Price USD$NVS is featured in our Shelley Moore Capito strategy.
All StrategiesRecent trades of NVS by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes in NVS holdings by institutional investors
Quarterly net insider trading by NVS's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
Disclaimer: The performance results shown are based on historical backtesting and are hypothetical in nature. Backtested performance does not represent actual trading and does not account for all market factors that may affect execution, such as liquidity, slippage, and changing market conditions. Past performance is not necessarily indicative of future results. There is no guarantee that any trading strategy will be profitable or avoid losses.
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More about Alpha -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More about Annual Standard Deviation -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More about Annual Volatility -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More about Beta -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More about CAGR -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More about Information Ratio -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More about Max Drawdown -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More about Sharpe Ratio -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More about Treynor Ratio -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
-
$40,000 Feb 04, 2003 Issue: Agriculture
NVS Estimated quarterly lobbying spending
NVS Revenue by Segment or Geography
New NVS patent grants
-
Patent Title: Synthetic apelin fatty acid conjugates with improved half-life Apr. 03, 2018
-
Patent Title: Carboxamide derivatives Apr. 03, 2018
-
Patent Title: Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders Apr. 03, 2018
-
Patent Title: Dual optic, curvature changing accommodative iol having a fixed disaccommodated refractive state Apr. 03, 2018
-
Patent Title: Edge design for reducing unwanted photic effects in intraocular lenses Apr. 03, 2018
-
Patent Title: Fast and automated segmentation of layered image with heuristic graph search Mar. 27, 2018
-
Patent Title: Compounds and compositions for the treatment of parasitic diseases Mar. 27, 2018
-
Patent Title: Vitrectomy probe with integral valve Mar. 27, 2018
-
Patent Title: Methods to identify macromolecule binding and aggregation prone regions in proteins and uses therefor Mar. 20, 2018
-
Patent Title: Low-water content acrylate-acrylamide copolymers for ophthalmic devices Mar. 20, 2018
-
Patent Title: Water-processable silicone-containing prepolymers and uses thereof Mar. 20, 2018
-
Patent Title: Method for producing ophthalmic lenses Mar. 20, 2018
-
Patent Title: Aspheric optical lenses and associated systems and methods Mar. 20, 2018
-
Patent Title: Acoustic pumps and systems Mar. 13, 2018
-
Patent Title: Method of separating excess lens forming material from a molded ophthalmic lens, in particular a contact lens Mar. 13, 2018
-
Patent Title: Combination of a pi3 kinase inhibitor with pacitaxel for use in the treatment or prevention of a cancer of the head and neck Mar. 13, 2018
-
Patent Title: Combination therapy Mar. 13, 2018
-
Patent Title: Benzothiazolone compound Mar. 13, 2018
-
Patent Title: Poly(oxazoline-co-ethyleneimine)-epichlorohydrin copolymers and uses thereof Mar. 06, 2018
-
Patent Title: Antibody molecules to lag-3 and uses thereof Mar. 06, 2018
-
Patent Title: Cyclic apelin derivatives for the treatment of heart failure Mar. 06, 2018
-
Patent Title: Cross-linking of eye tissue Mar. 06, 2018
-
Patent Title: Delivery system for ocular implant Mar. 06, 2018
-
Patent Title: Compounds and compositions as toll-like receptor 7 agonists Feb. 27, 2018
-
Patent Title: Ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors Feb. 20, 2018
-
Patent Title: Pyrimido[4,5-b]quinoline-4,5(3h, 10h)-dione derivatives Feb. 20, 2018
-
Patent Title: Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1 Feb. 20, 2018
-
Patent Title: Glycoside derivatives and uses thereof Feb. 20, 2018
-
Patent Title: Gonio lens system with stabilization mechanism Feb. 20, 2018
-
Patent Title: Imidazopyrrolidine derivatives and their use in the treatment of disease Feb. 13, 2018
-
Patent Title: Method and packaging plant for placing product packages into shipment containers Feb. 13, 2018
-
Patent Title: Antibody molecules to tim-3 and uses thereof Feb. 06, 2018
-
Patent Title: Pyridopyrimidinedione derivatives Feb. 06, 2018
-
Patent Title: Auristatin derivatives and conjugates thereof Feb. 06, 2018
-
Patent Title: Colored ink for pad transfer printing of silicone hydrogel lenses Jan. 30, 2018
-
Patent Title: Apparatus for dissecting an eye for the introduction of a photosensitizer Jan. 30, 2018
-
Patent Title: Contact lens mounting speculum for vitreoretinal surgery Jan. 30, 2018
-
Patent Title: Cuvette system and methods for the inspection of ophthalmic lenses Jan. 23, 2018
-
Patent Title: Peptides and compositions for treatment of joint damage Jan. 16, 2018
-
Patent Title: Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof Jan. 16, 2018
-
Patent Title: Methods for preparing squalene Jan. 16, 2018
-
Patent Title: Use of somatostatin analogs in control of hypoglycemia Jan. 16, 2018
-
Patent Title: Pharmaceutical combination comprising binimetinib Jan. 16, 2018
-
Patent Title: Method of treating atherosclerosis in high triglyceride subjects Jan. 16, 2018
-
Patent Title: Hydrophobic acrylate-acrylamide copolymers for ophthalmic devices Jan. 09, 2018
-
Patent Title: Method for characterizing an ophthalmic lens Jan. 09, 2018
-
Patent Title: Compositions and methods for antibodies targeting bmp6 Jan. 09, 2018
-
Patent Title: Polyomavirus neutralizing antibodies Jan. 09, 2018
-
Patent Title: Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors Jan. 09, 2018
-
Patent Title: Intraocular lens surgical system and method Jan. 09, 2018
Federal grants, loans, and purchases
Estimated quarterly amount awarded to NVS from public contracts
Recent insights relating to NVS
Recent picks made for NVS stock on CNBC
ETFs with the largest estimated holdings in NVS
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $NVS stock a Buy, Sell, or Hold?
- What is the price target for $NVS stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $NVS stock?
- Who owns the most shares of $NVS stock?
- What funds own $NVS stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view NVS Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, respiratory, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.
|
Name
|
Role
|
Salary
|
Bonus
|
Stock/Option Awards
|
Total Compensation
|
|---|